CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment.
CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens were evaluated before and during an anti-HCV regimen (interferon-alpha2a and ribavirin) in 36 patients coinfected with HCV and human immunodeficiency virus (HIV), to determine whether immune responses against HCV antigens are present in such patients, whether these responses are modified by anti-HCV treatment, and whether they are correlated with treatment efficacy. The CD4 responses against HCV antigens (primarily core antigens) detected at study entry in one-half of the patients did not correlate with anti-HCV treatment efficacy. Of 36 patients, 8 had patterns of persistent immune response to infection by genotypes 3 or 4 that were significantly correlated with sustained virologic response. Persistent immunologic reactivity and sustained virologic response coexisted only in patients infected with genotype 3. These findings suggest that HCV genotype may influence specific immune response, which, in turn, is implicated in virologic control.
Legrand
Elisabeth
E
Virology Laboratory, Bordeaux 2 University, France.
Neau
Didier
D
Galperine
Tatiana
T
Trimoulet
Pascale
P
Moreau
Jean-François
JF
Pitard
Vincent
V
Lacut
Jean-Yves
JY
Ragnaud
Jean-Marie
JM
Dupon
Michel
M
Le Bail
Brigitte
B
Bernard
Noëlle
N
Schvoerer
Evelyne
E
Houghton
Michael
M
Fleury
Hervé
H
Lafon
Marie-Edith
ME
D000328:Adult; D000998:Antiviral Agents / Q000494:pharmacology* / Q000592:standards / Q000627:therapeutic use; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D005260:Female; D016655:HIV Core Protein p24 / Q000276:immunology; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D015497:HIV-1 / Q000254:growth & development* / Q000276:immunology; D016174:Hepacivirus / Q000254:growth & development* / Q000276:immunology; D018936:Hepatitis C Antigens / Q000097:blood / Q000276:immunology*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000592:standards / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012254:Ribavirin / Q000592:standards / Q000627:therapeutic use*; D018709:Statistics, Nonparametric; D014373:Tuberculin / Q000276:immunology
D000998:Antiviral Agents; D016655:HIV Core Protein p24; D018936:Hepatitis C Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014373:Tuberculin; D012254:Ribavirin